Key Drivers
- Strong Cash Flow
- Margin Pressure
- Balance Sheet Risk
AIAI Summary
ILMN has shifted from a broken-turnaround story to a credible cash-flow recovery story, but with the stock already near ~20.6x FY2025 earnings, the key takeaway is that further upside now depends on sustained margin stabilization and clinical consumables adoption while research-budget sensitivity, China weakness, and sequencing competition keep a clean re-rating in check.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Margin Pressure
- •Balance Sheet Risk
ILMN remains a highly profitable, cash-generative business with strong FY2025 margins and returns, but rising leverage, softer recent-quarter margins, and a rich valuation make the stock dependent on continued cash flow growth.
Price Behavior
Key Price Behavior Insights:
- •Rebound strength
- •Higher highs
- •Near-term pullback
ILMN remains in an upward intermediate trend over the last month, with a sharp rebound from late-April lows, but it has pulled back from the recent $145.70 high and still needs a clean breakout to confirm the move.
Sharp rebound from $120.37 on 2026-04-29 to $145.70 on 2026-05-12, then a pullback from the peak
Sentiment & News
Key News Insights:
- •Earnings beat
- •Margin expansion
- •Buyback boost
Illumina delivered a Q1 revenue and EPS beat with margin expansion, a $1.5B buyback authorization, and raised guidance, fueling a strong positive market reaction and improving momentum.
The beat, higher outlook, and added capital return signal improving fundamentals and near-term upside for ILMN
Similar Companies in Healthcare
Other companies in the same sector with AI ratings